Department of Thoracic and Cardiovascular Surgery, Chonnam National University Hospital and Medical School, 160 Baekseo-ro, Dong-gu, Gwangju, 61469, Republic of Korea (South Korea).
Department of Pediatrics, Chonnam National University Children's Hospital and Medical School, Gwangju, 61469, Republic of Korea.
Tissue Eng Regen Med. 2022 Jun;19(3):537-551. doi: 10.1007/s13770-021-00422-4. Epub 2022 Feb 15.
We have designed a reinforced drug-loaded vascular graft composed of polycaprolactone (PCL) and polydioxanone (PDO) via a combination of electrospinning/3D printing approaches. To evaluate its potential for clinical application, we compared the in vivo blood compatibility and performance of PCL/PDO + 10%DY grafts doped with an antithrombotic drug (dipyridamole) with a commercial expanded polytetrafluoroethylene (e-PTFE) graft in a porcine model.
A total of 10 pigs (weight: 25-35 kg) were used in this study. We made a new 5-mm graft with PCL/PDO composite nanofiber via the electrospinning technique. We simultaneously implanted a commercially available e-PTFE graft (n = 5) and our PCL/PDO + 10%DY graft (n = 5) into the carotid arteries of the pigs. No anticoagulant/antiplatelet agent was administered during the follow-up period, and ultrasonography was performed weekly to confirm the patency of the two grafts in vivo. Four weeks later, we explanted and compared the performance of the two grafts by histological analysis and scanning electron microscopy (SEM).
No complications, such as sweating on the graft or significant bleeding from the needle hole site, were seen in the PCL/PDO + 10%DY graft immediately after implantation. Serial ultrasonographic examination and immunohistochemical analysis demonstrated that PCL/PDO + 10%DY grafts showed normal physiological blood flow and minimal lumen reduction, and pulsed synchronously with the native artery at 4 weeks after implantation. However, all e-PTFE grafts occluded within the study period. The luminal surface of the PCL/PDO + 10%DY graft in the transitional zone was fully covered with endothelial cells as observed by SEM.
The PCL/PDO + 10%DY graft was well tolerated, and no adverse tissue reaction was observed in porcine carotid models during the short-term follow-up. Colonization of the graft by host endothelial and smooth muscle cells coupled with substantial extracellular matrix production marked the regenerative capability. Thus, this material may be an ideal substitute for vascular reconstruction and bypass surgeries. Long-term observations will be necessary to determine the anti-thrombotic and remodeling potential of this device.
我们设计了一种由聚己内酯(PCL)和聚二氧杂环已酮(PDO)组成的强化载药血管移植物,通过静电纺丝/3D 打印方法将其组合在一起。为了评估其在临床应用中的潜力,我们在猪模型中比较了载有抗血栓药物(双嘧达莫)的 PCL/PDO+10%DY 移植物与商业膨体聚四氟乙烯(e-PTFE)移植物的体内血液相容性和性能。
本研究共使用了 10 头猪(体重:25-35kg)。我们通过静电纺丝技术用 PCL/PDO 复合纳米纤维制造了一种新的 5mm 移植物。我们同时植入了一种市售的 e-PTFE 移植物(n=5)和我们的 PCL/PDO+10%DY 移植物(n=5)到猪的颈动脉中。在随访期间未给予抗凝/抗血小板药物,每周进行超声检查以确认体内两种移植物的通畅性。四周后,通过组织学分析和扫描电子显微镜(SEM)比较两种移植物的性能。
PCL/PDO+10%DY 移植物植入后立即未见移植物出汗或针孔部位明显出血等并发症。连续超声检查和免疫组织化学分析表明,PCL/PDO+10%DY 移植物在植入后 4 周时显示正常的生理血流和最小管腔减少,并与原生动脉同步搏动。然而,所有 e-PTFE 移植物在研究期间均闭塞。SEM 观察到 PCL/PDO+10%DY 移植物过渡区的管腔表面完全被内皮细胞覆盖。
PCL/PDO+10%DY 移植物耐受良好,在猪颈动脉模型的短期随访中未观察到不良组织反应。宿主内皮和平滑肌细胞对移植物的定植以及大量细胞外基质的产生标志着其再生能力。因此,该材料可能是血管重建和旁路手术的理想替代物。需要进行长期观察以确定该装置的抗血栓和重塑潜力。